Mielnicka, N.; Dutka, M.; Kułak, K.; Kułak, A.; Tarkowski, R.
A New Direction in Endometrial Cancer Therapy—PD-1 and PD-L1 Immune Checkpoint Inhibitors—Where Will It Take Us? J. Clin. Med. 2025, 14, 8366.
https://doi.org/10.3390/jcm14238366
AMA Style
Mielnicka N, Dutka M, Kułak K, Kułak A, Tarkowski R.
A New Direction in Endometrial Cancer Therapy—PD-1 and PD-L1 Immune Checkpoint Inhibitors—Where Will It Take Us? Journal of Clinical Medicine. 2025; 14(23):8366.
https://doi.org/10.3390/jcm14238366
Chicago/Turabian Style
Mielnicka, Natalia, Martyna Dutka, Krzysztof Kułak, Anna Kułak, and Rafał Tarkowski.
2025. "A New Direction in Endometrial Cancer Therapy—PD-1 and PD-L1 Immune Checkpoint Inhibitors—Where Will It Take Us?" Journal of Clinical Medicine 14, no. 23: 8366.
https://doi.org/10.3390/jcm14238366
APA Style
Mielnicka, N., Dutka, M., Kułak, K., Kułak, A., & Tarkowski, R.
(2025). A New Direction in Endometrial Cancer Therapy—PD-1 and PD-L1 Immune Checkpoint Inhibitors—Where Will It Take Us? Journal of Clinical Medicine, 14(23), 8366.
https://doi.org/10.3390/jcm14238366